Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-03-22
2010-06-01
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S634000, C514S301000, C514S366000, C548S152000, C548S161000
Reexamination Certificate
active
07727979
ABSTRACT:
The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R′)— or —O— and R′ is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence. The above can be produced using generally used methods and processed to give medicaments.
REFERENCES:
patent: 4624956 (1986-11-01), Lazzarini et al.
patent: 4716228 (1987-12-01), Scarponi et al.
patent: 2206385 (1973-08-01), None
patent: 0 321 191 (1989-06-01), None
patent: 1140387 (1969-01-01), None
patent: 09-059258 (1997-04-01), None
patent: WO 02/24192 (2002-03-01), None
patent: WO 2004/083218 (2004-09-01), None
Marinko P, Kastelic J, Krbavcic A and Kikelj. A convenient sysnthesis of 4-aminomethyl-4,5,67-tetrahydro-1,3-benzothiazole arginine side-chain memetics. Tetrahedron Letters 42 (2001) 8911-8913.
Minault M, Lecron JC, Labrouche S, Simonnet G, and Gombert. characterization of binding sites for neuropeptide FF on T lymphocytes of the jurkat cell line. Peptide 16 (1995) 105-111.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Marinko et al ‘Tetrahedron letters’ 42 (2001) 8911-8913.
Yoshiro Usi, Annual Reports Takeda Research Laboratory, 1968, Research & Development Division Chemical Industries Ltd., vol. 27, Abstract.
Yang, et al., “Isolation, Sequencing, Synthesis, and Pharmacological Characterization of Two Brain Neuropeptides that Modulate the Action of Morphine”, PNAS, vol. 82, pp. 7757-7761, 1985.
Roumy, et al., “Neuropeptide FF, Pain and Analgesia”, European Journal of Pharmacology, vol. 345, pp. 1-11, 1998.
Panula, et al., “Neuropeptide FF, A Mammalian Neuropeptide with Multiple Functions”, Progress in Neurobiology, vol. 48, pp. 461-487, 1996.
Lake, et al., “IgG from Neuropeptide FF Antiserum Reverses Morphine Tolerance in the Rat”, Neuroscience Letters, vol. 132, pp. 29-32, 1991.
Elshourbagy, et al., “Receptor for the Pain Modulatory Neuropeptides FF and AF is an Orpahn G Protein-coupled Receptor”, The Journal of Biological Chemistry, vol. 275, No. 34, pp. 25965-25971, 2000.
Sundblom, et al., “Pulsatile Secretion of Neuropeptide FF into Human Blood”, Peptides, vol. 19, No. 7, pp. 1165-1170, 1998.
Bonini, et al., “Identification and Characterization of Two G Protein-coupled Receptors for Neuropeptide FF”, The Journal of Biological Chemistry, vol. 275, No. 50, pp. 39324-39331, 2000.
Kotani, et al., “Functional Characterization of a Human Receptor for Neuropeptide FF and Related Peptides”, British Journal of Pharmacology, vol. 133, pp. 138-144, 2001.
Allard, et al., “Characterization of Rat Spinal Cord Receptors to FLFQPQRFamide, a Mammalian Morphine Modulating Peptide: A Binding Study”, Brain Research, vol. 500, pp. 169-176, 1989.
Allard, et al., “Autoradiographic Distribution of Receptors to FLFQPQRFamide, a Morphine-Modulating Peptide, in Rat Central Nervous System”, Neuroscience, vol. 49, No. 1, pp. 101-116, 1992.
Gouarderes, et al., “Quantitative Autoradiographic Distribution of NPFF1Neuropeptide FF Receptor in the Rat Brain and Comparison with NPFF2Receptor by Using [125I]YVP and [125I]EYF as Selective Radioligands”, Neuroscience, vol. 115, No. 2, pp. 349-361, 2002.
Liu, et al., “Identification and Characterization of Novel Mammalian Neuropeptide FF-like Peptides that Attenuate Morphine-Induced Antinociception”, The Journal of Biological Chemistry, vol. 276, No. 40, pp. 36961-36969, 2001.
Lefrere, et al., “Neuropeptide AF and FF Modulation of Adipocyte Metabolism”, The Journal of Biological Chemistry, vol. 277, No. 42, pp. 39169-39178, 2002.
Malin, et al., “Analog of Neuropeptide FF Attenuates Morphine Abstinence Syndrome”, Peptides, vol. 12, pp. 1011-1014, 1991.
Prokai, et al., “Combinatorial Lead Optimization of a Neuropeptide FF Antagonist”, J. Med. Chem., vol. 44, pp. 1623-1626, 2001.
Mollereau, et al., “Pharmacological Characterization of Human NPFF1and NPFF2Receptors Expressed in CHO Cells by Using NPY Y1Receptor Antagonists”, European Journal of Pharmacology, vol. 451, pp. 245-256, 2002.
Quelven, et al., “Dissociation of Pharmacological Pro- and Anti-opioid Effects by Neuropeptide FF Analogs”, European Journal of Pharmacology, vol. 449, pp. 91-98, 2002.
Schnur, et al., “N-(5-Fluorobenzothiazol-2yl)-2-guanidinothiazole-4-carboxamide. A Novel, Systemically Active Antitumor Agent Effective Against 3LL Lewis Lung Carcinoma”, J. Med. Chem., vol. 34, pp. 914-918, 1991.
Tanaka, et al., “Antiplatelet Agents Based on Cyclooxygenase Inhibition without Ulcerogenesis. Evaluation and Synthesis of 4,5-Bis(4-methoxyphenyl)-2-substituted-thiazoles”, J. Med. Chem., vol. 37, pp. 1189-1199, 1994.
Yokoo, et al., “Synthesis of 1-Azacycloheptan-4-one Hydrochloride”, Studies on Seven-membered Heterocyclic Compounds Containing Nitrogen. I., vol. 29, No. 5, pp. 631-632, 1956.
Bertz, et al., “Organocopper Reagents in Dimethyl Sulfide”, Tetrahedron, vol. 45, No. 2, pp. 425-434, 1989.
Brummond, et al., “α-Chlorination of Ketones Using p-Toluenesulfonyl Chloride”, Tetrahedron Letters, vol. 40, pp. 2231-2234, 1999.
Mihovilovic, et al., “Asymmetric Baeyer-Villiger Oxidations of 4-Mono- and 4,4-Disubstituted Cyclohexanones by Whole Cells of EngineeredEscherichia coli”, J. Org. Chem. vol. 66, pp. 733-738, 2001.
Baigrie, et al., “Stereospecific Formation of Enolates from Reaction of Unsymmetrical Ketenes and Organolithium Reagents”, J. Am. Chem. Soc., vol. 107, No. 19, pp. 5391-5396, 1985.
De Jongh, et al., “Synthesis of Polyspiro Compounds Consisting of Cyclohexane Rings”, Tetrahedron, vol. 20, pp. 2553-2573, 1964.
Radivoy, et al., “Reduction of Sulfonates and Aromatic Compounds with the NiCl2*2H2O-Li-Arene (cat.) Combination”, Tetrahedron, vol. 55, pp. 14479-14490, 1999.
Ritter, “Synthetic Transformations of Vinyl and Aryl Triflates”, Synthesis, pp. 735-762, 1993.
Magnus, et al., “Application of the β-Azidonation Reaction to the Synthesis of the Antitumor Alkaloid (+)- Pancratistatin”, Tetrahedron, vol. 54, pp. 15509-15524, 1998.
Reetz, et al., “The Kharasch Reaction Revisited: CuX3Li2-catalyzed Conjugate Addition Reactions of Grinard Reagents”, Journal of Organometallic Chemistry, vol. 502, pp. C5-C7, 1995.
Parker, et al., “Enantioselective Synthesis of the Enyne A-Ring Synthon of the lα-Hydroxy Vitamins D”, J. Org. Chem., vol. 62, No. 19, pp. 6692-6696, 1997.
Cazaeu, et al., “A New Practical Synthesis of Silyl Enol Ethers. Part. I. From Simple Aldehydes and Ketones”, Tetrahedron, vol. 43, No. 9, pp. 2075-2088, 1987.
Reetz, et al., “tert-Alkylation of Ketones and Aldehydes”, Angew. Chem. Int: Ed. Engl. vol. 17, No. 1, pp. 48-49, 1978.
Sit, et al., “Novel Dihydropyrazine Analogues as NPY Antagonists”, Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 337-340, 2002.
Vilim, et al., “Gene for Pain M
Breu Volker
Caroff Eva
Fecher Anja
Fretz Heinz
Giller Thomas
Actelion Pharmaceuticals Ltd.
Hunton & Williams LLP
Padmanabhan Sreeni
Pihonak Sarah
LandOfFree
Guanidine derivatives and their use as neuropeptide FF... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanidine derivatives and their use as neuropeptide FF..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanidine derivatives and their use as neuropeptide FF... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177637